A Novel Bacterially-derived Product to Enhance Immunity and Response to Immune Checkpoint Therapy
一种新型细菌衍生产品,可增强免疫力和对免疫检查点治疗的反应
基本信息
- 批准号:10482027
- 负责人:
- 金额:$ 28.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-06 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:AdultAdverse effectsAgonistAntibioticsAspergillosisAwardBacteroides thetaiotaomicronBiochemicalBiodistributionBiological AssayBiological SciencesC57BL/6 MouseCD34 geneCD8-Positive T-LymphocytesCancer ModelCancer PatientCandidiasisCell WallChemistryClinicalClinical TrialsColorectal CancerCombined Modality TherapyCommunicable DiseasesCorrelative StudyDataDendritic CellsDoseEnhancersEthicsExposure toFaceFutureGene Expression ProfileGoalsHIVHeartHematopoietic stem cellsHepatitis BHumanImmuneImmune responseImmune systemImmunityImmunocompromised HostImmunooncologyImmunotherapyImplantIn Situ Nick-End LabelingIn VitroInfectionInjectionsInnovative TherapyInterleukin-12Interleukin-6IntestinesKidneyLabelLactobacillus acidophilusLeadLipopolysaccharidesLiverLymphocyteMC38MalariaMalignant NeoplasmsMaximum Tolerated DoseMeasuresMelanoma CellMethodsModelingMolecularMonoclonal AntibodiesMucormycosisMusMycosesOncologyOralOrganOrganismPathogenicityPathologyPatient-Focused OutcomesPatientsPatternPattern recognition receptorPhasePre-Clinical ModelProbioticsProteinsRiskSafetySepsisSerratia marcescensStainsStreptococcus pyogenesT cell responseT-LymphocyteTLR2 geneTLR4 geneTNF geneTestingTherapeuticTimeTissuesToxic effectToxinTransplantationWorkYogurtanti-CTLA4anti-PD-1anti-PD1 antibodiesanti-tumor immune responsearmbacterial lysatecheckpoint inhibitioncheckpoint therapycommensal bacteriacost effectivecytokinedesignearly phase clinical trialexperimental studyfecal transplantationgut bacteriagut colonizationgut microbiotahumanized mouseimmune checkpointimmunoregulationimprovedin vivo Modelinnovationinterestintraperitonealmelanomamicrobialmicrobiomemicrobiome therapeuticsnext generationnovelnovel therapeuticspathogenpathogenic bacteriapre-clinicalresponsesubcutaneoustumortumor growth
项目摘要
Abstract
Aumenta is developing a product derived from two commensal bacterial species for use as an innovative
immunologic therapy. The product is designed to augment multiple arms of the immune system, offering a
safe, novel and innovative therapy for unmet needs in treating infectious disease (e.g. fungal infections) and
enhancing the body's response to immuno-oncology therapies (e.g. immune checkpoint therapies for melanoma,
colorectal cancer). More than 100 years ago, Coley's toxin, a mix of heat-killed Streptococcus pyogenes and
Serratia marcescens, was used to stimulate the immune system and frequently resulted in tumor regression,
though it carried a risk of sepsis. Evidence from preclinical models, human patient correlative studies, and early
fecal microbiota transplant (FMT) clinical trials suggests that utilizing gut microbiota is a viable strategy to
enhance the host’s immune response. Immune system stimulation has the potential to improve the efficacy of
immune checkpoint therapy (ICT) in cancer patients. Similar to cancers, multiple pathogens take advantage of
immune checkpoints to evade immune control, including malaria, HIV and hepatitis B. The use of ICT is also of
special interest in treating fungal infections, such as mucormycosis, aspergillosis, and candidiasis in
immunocompromised patients. However, the current paradigm of microbiome therapeutics—namely oral
probiotics or FMT—is fraught with challenges, including safety, ability to sustain gut colonization, ethical
concerns about introducing live organisms into patients, and potential FDA regulatory hurdles. To overcome
these challenges, Aumenta’s product is derived from lysates of two commensal gut bacteria associated
with a positive response to ICT in adult melanoma patients: the Gram-negative Bacteroides thetaiotaomicron
(Bt) and Gram-positive Faecalibacterium prausnitzii (Fp). Through this Bt/Fp microbial lysate (BFML), we aim to
augment multiple arms of the immune system via specific bacterial pathogen-associated molecular patterns
(PAMPs) that modulate the immune response and that prime CD4 and CD8 T cell responses. In the proposed
work, we plan to 1) Determine the maximum tolerated dose in healthy mice and the dose response of BFML in
mice with melanoma and colorectal cancer receiving ICT, 2) Demonstrate translatability to humans in relevant
in vitro and in vivo models, and 3) Determine the biodistribution of BFML using a click chemistry/fluorescent
labeling method, which will provide valuable information on safety and the mechanism of action. Successful
completion of these aims will allow Aumenta to seamlessly transition into a Phase II award, initiate IND-enabling
studies, and begin planning our manufacturing, regulatory, and clinical trial strategies. Immune-enhancing
microbial therapies like BFML have the potential to extend the efficacy of immunotherapy to greater numbers of
cancer patients and to open new avenues for treating challenging infections.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREW Y KOH其他文献
ANDREW Y KOH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREW Y KOH', 18)}}的其他基金
Mentoring Patient Oriented Research in the Microbiome of Cancer and Stem Cell Transplant Patients
指导癌症和干细胞移植患者微生物组的以患者为导向的研究
- 批准号:
10593178 - 财政年份:2020
- 资助金额:
$ 28.92万 - 项目类别:
Mentoring Patient Oriented Research in the Microbiome of Cancer and Stem Cell Transplant Patients
指导癌症和干细胞移植患者微生物组的以患者为导向的研究
- 批准号:
10370367 - 财政年份:2020
- 资助金额:
$ 28.92万 - 项目类别:
Candida Albicans Gastrointestinal Colonization and Dissemination
白色念珠菌胃肠道定植和传播
- 批准号:
9360089 - 财政年份:2016
- 资助金额:
$ 28.92万 - 项目类别:
Candida Albicans Gastrointestinal Colonization and Dissemination
白色念珠菌胃肠道定植和传播
- 批准号:
9761967 - 财政年份:2016
- 资助金额:
$ 28.92万 - 项目类别:
Mucosal colonization and dissemination of P. aeruginosa
铜绿假单胞菌的粘膜定植和传播
- 批准号:
8079391 - 财政年份:2005
- 资助金额:
$ 28.92万 - 项目类别:
Mucosal colonization and dissemination of P. aeruginosa
铜绿假单胞菌的粘膜定植和传播
- 批准号:
6856404 - 财政年份:2005
- 资助金额:
$ 28.92万 - 项目类别:
Mucosal colonization and dissemination of P. aeruginosa
铜绿假单胞菌的粘膜定植和传播
- 批准号:
7389572 - 财政年份:2005
- 资助金额:
$ 28.92万 - 项目类别:
Mucosal colonization and dissemination of P. aeruginosa
铜绿假单胞菌的粘膜定植和传播
- 批准号:
7036597 - 财政年份:2005
- 资助金额:
$ 28.92万 - 项目类别:
Mucosal colonization and dissemination of P. aeruginosa
铜绿假单胞菌的粘膜定植和传播
- 批准号:
7210688 - 财政年份:2005
- 资助金额:
$ 28.92万 - 项目类别:
Mucosal colonization and dissemination of P. aeruginosa
铜绿假单胞菌的粘膜定植和传播
- 批准号:
7595766 - 财政年份:2005
- 资助金额:
$ 28.92万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 28.92万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 28.92万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 28.92万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 28.92万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 28.92万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 28.92万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 28.92万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 28.92万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 28.92万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 28.92万 - 项目类别:
Studentship